Sapient leverages its next-generation mass spectrometry approaches to probe deeper into the human metabolome at a rate is unmatched for discovery, uncovering previously unknown biomarkers that associate with early disease, disease progression, and drug response. By enabling sponsors rapidly identify, validate, and translate these novel biomarkers, we help accelerate their drug development programs, enrich clinical… Continue reading Untargeted Metabolomics Services for an Unprecedented Scale of Biomarker Discovery
Untargeted Metabolomics Services for an Unprecedented Scale of Biomarker Discovery
![untargeted metabolomics services cro](https://sapient.bio/wp-content/uploads/2023/04/untargeted-metabolomics-services-cro.png)